Skip to contentX
Xenon Pharmaceuticals Inc.
X
XENEXenon Pharmaceuticals Inc. Q4 2017 · 10-K
Revenue$16.00K$16.00K−95.7% vs Q4 2016 Net Income-$8.07M-$8.07MN/M vs Q4 2016 EPS Diluted-$0.45-$0.45N/M vs Q4 2016 Operating Income-$8,051,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Xenon Pharmaceuticals Inc. · CIK 1582313 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$6,901,000N/M Margins · derivedOperating margin-50318.8%−48866.1 pt vs Q4 2016
Net margin-50406.3%−48809.4 pt vs Q4 2016
ended Dec 31, 2017 · filed Mar 7, 2018 · 66 d after period end